Understanding SGLT2 Inhibitors

July 12, 2016
Samantha J. Peterson

This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.

This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.Session 3-CT-MPD17. SGLT2 Inhibitors-Understanding the Benefits and the Risks-And the Beat Goes On. ADA Scientific Sessions, New Orleans, LA. June 11, 2016. 

Understanding SGLT2 Inhibitors.

Safety and Efficacy of Dapagliflozin (DAPA) in Combination with Potassium (K)-sparing Agents

effects of DAPA 10 mg vs. placebo in patients treated with K-sparing agents

DAPA and potassium-sparing agents study results

Impact of Exposure to SGLT2 Inhibitors on Incidence of Diabetic Ketoacidosis among Danish Type 2 Diabetes Patients

SGLT2 inhibitors and DKA incidence

DKA hazard ratios

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

Trial assessed changes in HbA1c, body weight, systolic BP, and albuminuria with placebo or DAPA 10 mg

DAPA, CV risk factors, and renal function

Take-home points

PreviousNext

Related Content:

ADADiabetes
Dapagliflozin Effective for Reducing CV Risk in Diabetes, Irrespective of Kidney Function
Race, Gender, & Income Influence Access to SGLT2 Inhibitors Among US Patients
Low-Intensity Walking Program Fails to Show Benefit for Peripheral Artery Disease